About Us: Leadership
Brian P. McVeigh, MBA, CPA, CMA, CLP
Chief Executive Officer
Brian McVeigh is the Chairman, Chief Executive Officer, and Co-Founder of Code Bio. He also serves as the Executive Chairman of Redpin Therapeutics, Chairman of the Board of Genisphere, LLC, Board Observer of Araris Biotech AG, and is a Venture Partner with 4BIO Capital.
Brian has held leadership roles in both private and public biotechs, including a 25-year career with GlaxoSmithKline (GSK) Pharmaceuticals where he most recently served as the Vice President of Worldwide Business Development Transactions and Investment Management. In that capacity, he oversaw the assessment, negotiation, and execution of more than 100 business development transactions and managed GSK R&D’s $500+ million portfolio of equity investments in biotech collaboration partners and venture capital funds.
Brian holds Bachelor of Science degrees in Accounting and Finance from LaSalle University, an MBA with a Concentration in Finance from Villanova University, a Post MBA Certificate in Pharmaceutical Marketing from Saint Joseph's University, and a Certificate of Professional Development from the Wharton Business School at the University of Pennsylvania. He is a Certified Public Accountant, Certified Management Accountant, and Certified Licensing Professional.
Dave Anderson, PhD
Chief Scientific Officer
Dave Anderson serves as Code Bio’s Chief Scientific Officer. He is responsible for guiding the long-term vision for research and discovery and for driving Code Bio’s overall scientific strategy in Duchenne Muscular Dystrophy (DMD), Type 1 Diabetes (T1D), and other serious diseases. Dave leads efforts across research, discovery, translational medicine, regulatory strategy, and early development.
Prior to joining Code Bio, Dave served as Senior Vice President, Research at SwanBio Therapeutics directing translation of genetic therapies in development for the treatment of rare neurological diseases of the spinal cord. Prior to his role at SwanBio, Dave directed all preclinical research for the treatment of neurological diseases at Spark Therapeutics, Inc., where he oversaw development and growth of the central nervous system portfolio and team during his tenure.
Beyond his experience with SwanBio and Spark, Dave also co-founded two early-stage biotechnology companies, and previously served as faculty at Thomas Jefferson University. His expertise includes all aspects of experimental design and management with significant experience in molecular discovery and translation of basic research into preclinical animal models to support drug development.
Dave received a PhD in Molecular and Cell Biology from Thomas Jefferson University in 2005 and a B.Sc./Hons in Biomedical Sciences from Sheffield Hallam University in 1996.
Chief Operating Officer
As Code Bio’s Chief Operating Officer, Erin is leading corporate strategy and focusing on the buildout of the broader organization, with oversight of finance, manufacturing, human resources, information technology, legal, compliance, real estate and facilities, program and project management, corporate communications, and early commercial strategy. She brings to this role extensive experience in the pharmaceutical and biotechnology industry including more than 20 years with GlaxoSmithKline Pharmaceuticals where she held positions of increasing responsibility enterprise-wide across R&D and commercial businesses. Most recently she served as Vice President, Corporate Development at Passage Bio, a fully integrated gene therapy company. Erin holds a Bachelor of Arts degree from Franklin & Marshall College. She also completed the Transformational Leadership for Executives program through Wharton Business School at the University of Pennsylvania, as well as professional certifications in Executive Coaching and Alliance Management. Erin is currently an Executive Board member for Life Sciences Pennsylvania.
Keith G. Dewedoff
Interim Chief Financial Officer
As Code Bio’s CFO, Keith brings more than 20 years of experience in the life science industry, ranging from biotech venture-backed start-ups to commercial publicly traded companies. Keith also serves as a CFO and Advisor for Danforth Advisors, an advisory firm focused on providing financial strategy to life science specific organizations. He previously served as CFO of Ceptur Therapeutics and more than 10 other privately held & public companies at various life cycle stages, during which time he managed finance, accounting, corporate development, and other corporate operational functions.
Prior to Danforth, Keith was CFO of Kaizen Bioscience where he is still active on the board as Chair. Keith’s core expertise includes financial strategic planning, corporate and business development, portfolio management, fundraising and mergers & acquisitions. Prior to acting as a CFO, Keith was in financial & strategy leadership roles for various biotechnology organizations and private equity funds focused on distressed commercial & preclinical assets in need of portfolio optimization.
Keith holds a Bachelor of Science degree in Economics & Management from Northeastern University where he began his career as a research analyst advising research institutions and VC firms on portfolio planning strategies. While working in the UK, he also studied graduate work at Imperial College London that eventually led to a MSc program in Nanomedicine at Oxford University, where he is an alumni member of Kellogg College. Keith also is an active member of the Investments & Wealth Institute.
Robert C. Getts, Ph.D.
Chief Platform Technologies Officer
Dr. Bob Getts serves as Chief Platform Technologies Officer and is a Co-Founder of Code Bio. Bob leads all of the company’s discovery, platform development and novel application activities. He also serves as a Scientific Advisor for AllerGenis LLC; as a member of the Rowan University Biomedical Engineering Industrial and Medical Advisory Board; as an Associate Clinical Preceptor of Pharmacy and Therapeutics at the University of Pittsburgh School of Pharmacy; and as a graduate program advisor at Thomas Jefferson University and The University of Maryland.
Bob possesses more than 25 years of experience using nanotechnologies as tools to develop life science reagents, kits, and diagnostic assays. Most recently he served as the Chief Scientific Officer and acting CEO at Genisphere, LLC. where he led the development of 3DNA as a novel non-viral targeted delivery platform for the delivery of multiple types of therapeutic cargo including small drugs, siRNA, biologics, and whole genes.
Bob has a Ph.D. in Biochemistry from Lehigh University, has over 40 peer-review publications, abstracts, and presentations, and is listed as an inventor on more than 20 issued patents and over 35 U.S. and international patent applications.
Lauren M. Kaskiel, MBA
Chief Business Officer
Lauren Kaskiel has 20 years of experience in the biotech and pharmaceutical industry and joins Code Bio from Spark Therapeutics where she most recently served as Head of Program and Alliance Management. During her time at Spark, Lauren held roles in Alliance Management, New Product Planning and Program Management and established and managed key strategic relationships on gene therapy programs with Pfizer and Novartis. Lauren most recently served as a liaison with the Roche Group to support engagement and interactions during the first year following the acquisition of Spark by the Roche Group in December of 2019, and contributed to defining the operating model and governance for Spark and served as Chief of Staff to the Executive Team. Previously, Lauren was at GlaxoSmithKline (GSK) in research, operations, strategy, and alliance management roles. As part of GSK’s Worldwide Business Development team, Lauren managed over 20 alliances with biotech, diagnostic and venture partners.
She holds a Bachelor of Science degree in Biotechnology with a Minor in Microbiology from Pennsylvania State University and an MBA with a Concentration in Marketing from Drexel University. She has her Certificate of Achievement in Alliance Management (CA-AM) through the Association of Strategic Alliance Professionals (ASAP), is President of the ASAP Tri-State Chapter, and is a frequent guest lecturer at both Penn State and Drexel Universities.
Lori A. Getts, Ph.D.
Head of Process Development and Preclinical Production
Dr. Lori Getts is the Head of Process Development and Preclinical Production, and a Co-Founder of Code Bio. Lori leads the process scale up, CMC, and preclinical development functions for all of our pipeline programs. She has 20+ years’ experience in the biotech industry, developing therapeutic drug delivery platforms for targeted therapeutics, as well as developing and commercializing reagents and research kits used in a variety of biological assays throughout the life sciences and diagnostic sectors.
Lori was most recently the Vice President of Preclinical and Process Development at Genisphere, LLC where she played a pivotal role in the development of the 3DNA platform. She also directed the manufacture and QC of Genisphere’s entire reagents and research kit product line (over 135 products) including the OEM manufacture of the company’s flagship product, FlashTag®.
Lori is a co-author of many posters and papers as well as a co-inventor on several of the company’s patents and patent applications. She received her Ph.D. in Chemistry (Biochemistry focus) from Lehigh University and completed her Ph.D. thesis at Fox Chase Cancer Center where she used ovarian cancer model systems to study ovarian cancer etiology.